TL;DR

CrossSense has won the £1m Longitude Prize on dementia for AI software embedded in smart glasses that guides wearers through daily tasks. In testing, participants with dementia correctly identified 82% of household items while wearing the glasses, up from 46% without them — and the benefit persisted after removal.

A Conversational AI Companion

The winning technology pairs a camera-equipped pair of chunky, black-rimmed smart glasses with an AI assistant called Wispy. Rather than offering simple one-off reminders, Wispy provides real-time prompts during tasks through verbal cues and floating text, asks questions, and engages in light conversation to aid reminiscence.

The Longitude Prize on dementia, delivered by Challenge Works with support from Nesta and funded by Alzheimer’s Society and Innovate UK, aimed to encourage technology that helps people with the condition maintain independence. With roughly 150 million people expected to be living with dementia globally by 2050, the need for practical assistive tools is growing.

The Numbers Behind the Breakthrough

Prof Julia Simner of the University of Sussex tested CrossSense with 23 pairs of people living with dementia and their carers. Without the glasses, participants named only 46% of household items correctly. With them, accuracy rose to 82%. An hour after removing the glasses, participants still scored 78%, suggesting the AI prompts reinforce memory rather than simply substituting for it.

CrossSense chief executive Szczepan Orlins said the prize money will fund a four-week pilot in people’s homes later in 2026, with a smartphone version expected by the end of the year and smart glasses available in early 2027.

Practical Hurdles Remain

The technology is expected to cost about £50 per month, with the glasses themselves priced at up to £1,000 — though costs may fall. The initial target is direct consumer sales, with NHS availability planned as a longer-term goal.

Dr Foyzul Rahman of Loughborough University, who was not involved in the project, flagged that battery life of just one hour — requiring a portable power bank — could limit real-world adoption. He also called for larger randomised trials and raised ethical questions about data collection from vulnerable users.

Looking Forward

For the UK’s healthtech sector, CrossSense demonstrates that AI can move beyond chatbots and productivity tools into meaningful care applications. If the 2026 pilot confirms the early results, the technology could offer a practical route to extending independence for dementia patients — though affordability and NHS integration will determine whether it reaches the people who need it most.